Menu
Search
|

Menu

Close
X

scPharmaceuticals Inc SCPH.OQ (NASDAQ Stock Exchange Global Market)

5.06 USD
-0.43 (-7.83%)
As of 2:08 PM EDT
chart
Previous Close 5.49
Open 5.50
Volume 13,000
3m Avg Volume 38,492
Today’s High 5.50
Today’s Low 5.06
52 Week High 18.17
52 Week Low 5.06
Shares Outstanding (mil) 18.54
Market Capitalization (mil) 101.80
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.33 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-0.471
FY17
-2.449
FY16
-2.393
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.20
Price to Sales (TTM)
vs sector
--
8.07
Price to Book (MRQ)
vs sector
1.04
4.28
Price to Cash Flow (TTM)
vs sector
--
22.38
Total Debt to Equity (MRQ)
vs sector
11.60
17.39
LT Debt to Equity (MRQ)
vs sector
10.03
13.21
Return on Investment (TTM)
vs sector
--
13.23
Return on Equity (TTM)
vs sector
--
15.28

EXECUTIVE LEADERSHIP

John Tucker
President, Chief Executive Officer, Director, Since
Salary: --
Bonus: --
Troy Ignelzi
Chief Financial Officer, Since
Salary: --
Bonus: --
Abraham Ceesay
Chief Operating Officer, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Medical Equipment, Supplies & Distribution
Address:

2400 District Ave Ste 310
BURLINGTON   MA   01803-5239

Phone: +1617.5170730

scPharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in developing pharmaceutical products for subcutaneous delivery. The Company offers sc2Wear Infusor, which is a small pump that attaches to the body using a standard medical adhesive. The sc2Wear Infusor injects the drug into the body slowly, similar to an intravenous (IV) drip. The Company's products administered subcutaneously through the sc2Wear Infusor. The Company’s pipeline programs include: scFurosemide lead product candidate, Furoscix, consists of its proprietary subcutaneous formulation of furosemide delivered via sc2Wear Infusor for diuresis in heart failure patients outside of the acute care setting. The Company has completed two pivotal clinical studies, four exploratory clinical studies, and 12 human factor studies for Furoscix, and scCeftriaxone an antibiotic used intravenously for the treatment of infections caused by gram-positive and gram-negative organisms.

SPONSORED STORIES